ASSESSING THE FEASIBILITY AND DESIRABILITY OF A DIGITAL CARE PLAN FOR MANAGING IRRITABLE BOWEL SYNDROME IN INDIA
Main Article Content
Keywords
Digital care plan, irritable bowel syndrome, non-pharmacological interventions, participant adherence, participant satisfaction
Abstract
Digital health interventions (DHIs) are transforming chronic disease condition management by providing accessible, personalized, evidence-based interventions through digital platforms, such as smartphone applications. Irritable bowel syndrome (IBS), a chronic gastrointestinal disorder, affects 4.0%–7.9% of Indians. Given the short-term relief from conventional treatments, many individuals explore non-pharmacological interventions (NPIs) for desiring better management of their symptoms over the long term. This market research survey of 157 adults with IBS in India evaluated the feasibility and desirability of a 14-week digital care plan (DCP) incorporating NPIs, like a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP), cognitive behavioral therapy (CBT), and physical wellness practices involving mind–body–breath (MBB) interventions. It assessed participant adherence and satisfaction rates at weeks 1, 7, and 14. Participants reported high satisfaction with dietary wellness components, particularly during the elimination (average rating 7.9/10) and reintroduction (9.2/10) diet phases, and their perceptions of symptom relief and life quality. Feasibility was reflected by participant adherence to DCP till week 7; however, it reduced by week 14. The findings highlight the potential of integrating such well-designed DCPs along with the current standard of care to enhance personalized care, satisfaction, and engagement for patients with IBS in India to help themselves take responsibility toward better outcomes.
References
2. Jactel SN, Olson JM, Wolin KY, et al. Efficacy of a Digital Personalized Elimination Diet for the Self-Management of Irritable Bowel Syndrome and Comorbid Irritable Bowel Syndrome and Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2023;14(1):e00545.
3. Brenner DM, Ladewski AM, Kinsinger SW. Development and Current State of Digital Therapeutics for Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2024;22(2):222-34.
4. Rassi-Cruz M, Valente F, Caniza MV. Digital therapeutics and the need for regulation: how to develop products that are innovative, patient-centric and safe. Diabetol Metab Syndr. 2022;14(1):48.
5. Machała-Ćwikła E, Łapińska U, Zdziebło P, et al. Effect of physical activity on the severity of irritable bowel syndrome (IBS) symptoms. Quality in Sport. 2024;16.
6. Black CJ, Ford AC. Rational investigations in irritable bowel syndrome. Frontline Gastroenterol. 2020;11(2):140-7.
7. Carbone F, Van den Houte K, Besard L, et al. Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut. 2022;71(11):2226-32.
8. Guido V, Pontet Y, Lopez V, et al. Prevalence of irritable bowel syndrome and other functional gastrointestinal disorders in Uruguay. Rev Gastroenterol Mex (Engl Ed). 2024;89(2):258-64.
9. Saroj A, Tripathi A, Rungta S, et al. Psychiatric Co-Morbidities and Profile of Patients with Irritable Bowel Syndrome in Northern India. Brain Sci. 2024;14(4).
10. Dai YK, Wu YB, Li RL, et al. Efficacy and safety of non-pharmacological interventions for irritable bowel syndrome in adults. World J Gastroenterol. 2020;26(41):6488-509.
11. Peyton L, Greene J. Irritable bowel syndrome: current and emerging treatment options. P t. 2014;39(8):567-78.
12. Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44.
13. Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-40.
14. Fukudo S, Okumura T, Inamori M, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol. 2021;56(3):193-217.
15. Irritable Bowel Syndrome in Adults: Diagnosis and Management of Irritable Bowel Syndrome in Primary Care. National Institute for Health and Clinical Excellence: Guidance. London2008.
16. Matsueda K, Fukudo S, Ogishima M, et al. Efficacy and safety of peppermint oil for the treatment in Japanese patients with irritable bowel syndrome: a prospective, open-label, and single-arm study. Biopsychosoc Med. 2024;18(1):3.
17. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395-402.
18. Awad A, Trenfield SJ, Pollard TD, et al. Connected healthcare: Improving patient care using digital health technologies. Adv Drug Deliv Rev. 2021;178:113958.
19. Georgeff M. Digital technologies and chronic disease management. Aus Fam Phy 2014;43(12):842-6.
20. Eriksson EM, Andren KI, Kurlberg GK, et al. Aspects of the non-pharmacological treatment of irritable bowel syndrome. World J Gastroenterol. 2015;21(40):11439-49.
21. Bohm AK, Jensen ML, Sorensen MR, et al. Real-World Evidence of User Engagement With Mobile Health for Diabetes Management: Longitudinal Observational Study. JMIR Mhealth Uhealth. 2020;8(11):e22212.
22. Spartz EJ, DeDecker L, Le D, et al. Advances in Mobile Health for Inflammatory Bowel Disease. Diagnostics (Basel). 2022;13(1).
23. Sperber AD, Dumitrascu D, Fukudo S, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2017;66(6):1075-82.
24. Ghoshal UC, Sachdeva S, Pratap N, et al. Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology. Indian J Gastroenterol. 2023;42(2):249-73.